The Pharmaceutical Benefits Scheme (PBS) included Empagliflozin, a sodium glucose co transporter 2 (SGLT2) inhibitor, for chronic heart failure (CHF) treatment with reduced ejection fraction (LVEF ≤40%) starting April 1, 2022. Yet, the Pharmaceutical Benefits Advisory Committee (PBAC)decided in November 2022 not to endorse Empagliflozin for treating CHF in patients with a left ventricular ejection fraction over 40%. They based their decision on the high unmet clinical need and the economic model’s failure to capture the disease’s progressive nature adequately. A price reduction and risk sharing arrangement were required.
The PBAC has recommended an extension to the current empagliflozin listing on an updated addendum.This extension will include a General Schedule Authority Required (Streamlined) listing. It will be for the treatment of chronic heart failure in patients. These patients have a left ventricular ejection fraction greater than 40%. This recommendation comes after the sponsor addressed the outstanding issues. Also, the cost-effectiveness of the treatment is acceptable at the proposed price.
The PBAC observed a significant improvement in efficacy when adding Empagliflozin to standard care for this patient group. They based this observation on the primary composite outcome in EMPEROR-Preserved studies. These studies measured the time to the first cardiovascular death or hospitalisation for heart failure.
Addressing Outstanding Issues:
In conclusion, the sponsor has addressed significant outstanding issues identified in the November 2022 PBAC meeting. This was achieved through a proposed price reduction and risk sharing arrangement. The PBAC’s recommendation for listing was based on its assessment that the cost-effectiveness of Empagliflozin would be acceptable at the revised offer price of 16 December 2022.
Explore how Health Economics and Outcomes Research (HEOR) is shaping the future of global healthcare. Read our latest article to learn more about the strategic approaches being adopted to maximise the impact of HEOR. #Healthcare #HEOR #GlobalHealthcare 🌍🩺📊 Read more here
🌍 Exciting news! 🎉 Aga Khan University and the University of Michigan are joining forces to establish a data science hub in Kenya 🇰🇪. Using AI and machine learning, they aim to improve health equity and care delivery 🏥. #DataScience #AI #HealthEquity #Collaboration
Explore the key takeaways from the CHMP February 2024 meeting. From new vaccines to innovative disease treatments, the future of healthcare is promising. Read our latest article to learn more. #CHMP2024 #HealthcareInnovation #NewDrugApprovals 🏥🔬🧬
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.